Brief: Moleculin Biotech Completes Dosing In Part A Of Miracle Trial Data Readout On Track For Q1 2027
30/10/2026 12:54
BRIEF-Moleculin Biotech Completes Dosing In Part A Of Miracle Trial Data Readout On Track For Q1 2027 Oct 30 (Reuters) - Moleculin Biotech Inc MBRX.O:
MOLECULIN BIOTECH - COMPLETES DOSING IN PART A OF MIRACLE TRIAL; DATA READOUT ON TRACK FOR Q1 2027 - SEC FILING
Further company coverage: MBRX.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Moleculin Biotech
See all newsMoleculin Biotech Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Moleculin Secures Australian Patent For Annamycin Formulation Technology
Moleculin Biotech Inc expected to post a loss of $8.87 a share - Earnings Preview
Brief: Moleculin Biotech Completes Dosing In Part A Of Miracle Trial Data Readout On Track For Q1 2027
NASDAQ RESUMED AT 09:00 AM